Comparing the current results to its competitors, Perspective Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 0 % year on year. The revenue growth was below Perspective Therapeutics Inc 's competitors' average revenue growth of 79.32 %, achieved in the same quarter.
October 20, 2025
Perspective Therapeutics Inc., a company specializing in innovative radiopharmaceuticals for cancer treatment, has recently shared updated interim data from its ongoing Phase 1/2a clinical trial of ^212PbVMT-NET at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. This trial focuses on patients with unresectable or metastatic neuroendocrine tumors (NETs) expressing the somatostatin receptor type 2 (SSTR2).The ESMO Congress, taking place from October 17-21, 2025, provides a global platform for researchers and healthcare professionals to discuss the latest advancements in cancer treatment. Perspective s presentation attracted attention, as it reflects the company’s commitment...
April 11, 2025
In a significant milestone for Perspective Therapeutics Inc. (CATX), the company recently announced that the first patient has been dosed with 212PbVMT01 as a monotherapy in the Phase 1/2a study targeting MC1R-positive metastatic melanoma. This marks a critical step in the company’s ongoing commitment to innovating treatment options for patients suffering from this aggressive form of skin cancer. The administration of this therapy not only underlines the therapeutic potential of 212PbVMT01 but also positions Perspective Therapeutics within a competitive and lucrative segment of the biotechnology industry. As noted in the company’s financial performance, its return on assets (ROA) in the fourth quarter of...
November 21, 2024
Forging New Frontiers in Cancer Treatment: Perspective Therapeutics Amplifies Hope with 212PbVMTNET Trial Progress In the ever-evolving realm of cancer treatment, innovation is paramount. This week, at the esteemed 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium in Chicago, all eyes are on Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX). The radiopharmaceutical company, renowned for its avant-garde approach to oncological solutions, is ready to escalate the stakes, announcing significant developments in its Phase 1/2a clinical trial of ^212PbVMT-NET.Perspective Therapeutics, with its resolve firmly rooted in pioneering frontiers, has seamlessly amalgamat...
October 10, 2024
In an era where cancer treatment continues to evolve, Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a leading radiopharmaceutical company, is set to present groundbreaking research at several prestigious international medical congresses. These platforms will spotlight the company’s novel approaches to combating cancer, particularly with its innovative products that leverage advanced therapeutic technologies.The company recently unveiled that initial results from its Phase 1/2a study of ^212PbVMT01 will be featured in a poster presentation at the 21st International Congress of the Society for Melanoma Research (SMR), taking place from October 10-13, 2024, in New Orleans, Louisiana. This study marks ...
September 30, 2024
Perspective Therapeutics to Present Pioneering Data and Expound on FDA Fast Track Designation at EANM Annual Congress SEATTLE, Sept. 30, 2024 - Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), an innovative leader in the radiopharmaceutical space, continues to reinforce its commitment to advancing cancer treatment. The company is set to present updated preclinical data on its promising radiopharmaceutical candidate, PSV359, at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM). This prestigious event will take place in Hamburg, Germany, from October 19 to 23, 2024. The company will also exhibit findings from investigator-initiated studies on other proprietary assets, furth...
May 24, 2024
Perspective Therapeutics Announces $80 Million Underwritten Offering Amidst Expanding Innovations in Cancer Treatment Seattle, May 24, 2024 Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a leading radiopharmaceutical company pioneering advanced treatment applications for cancers throughout the body, has announced the pricing of an underwritten offering of its common stock and pre-funded warrants valued at approximately $80 million. This significant financial move underscores the company s commitment to advancing cancer treatment and broadening its innovative solutions in the medical field.The offering, expected to close on or around May 29, 2024, includes 51,515,880 shares of common stock priced a...
April 30, 2024
The company revealed the news on April 30, 2024, drawing attention to its continued pioneering efforts in creating advanced therapeutic applications for various forms of cancer. The FDA’s decision to include Perspective Therapeutics and their revolutionary treatment in the CDRP program gives a nod to their commendable work in this field, as well as their potential to create influential strides in the medical world more precisely, in the realm of NETs treatment.NETs, a unique type of malignancy developing in the neuroendocrine cells scattered throughout the body, can trigger a variety of diseases depending on the location of the tumor. The innovative therapy from Perspective Therapeutics, ^212PbVMTNET, is...
March 4, 2024
In a significant development, Perspective Therapeutics, a pioneering radiopharmaceutical company, announced an investment agreement with a group of institutional accredited investors. The company aims to raise approximately $87.4 million through a private placement, with the proceeds dedicated to advancing their advanced treatment applications for cancers across the body. This groundbreaking announcement marks a significant milestone for Perspective Therapeutics and has significant implications for the company s growth and contribution to the field of cancer therapeutics.The private placement represents a strategic move by Perspective Therapeutics to align itself with institutional accredited investors who p...
Publicly Traded Peers of Perspective Therapeutics Inc
Plus Therapeutics Inc Share Performance
-0.83%
Over The Past 5 Days
Plus Therapeutics Inc
Profile
Plus Therapeutics Inc is a biotechnology company that focuses on developing precision nanoparticles for targeted therapy. They utilize their proprietary technology to create and commercialize innovative drugs for the treatment of cancer and other diseases.
Actinium Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of targeted therapies for the treatment of various cancers.
Bluebird Bio Inc's business model focuses on developing gene therapies for severe genetic diseases and cancer. They collaborate with academic and industry partners to leverage their gene editing and cell-based technologies for discovering potential treatments and advancing these therapies through clinical trials.
Curis Inc's business model revolves around the development and commercialization of innovative cancer therapies. They focus on discovering and advancing drug candidates targeting specific molecular pathways involved in cancer growth and survival. The company collaborates with pharmaceutical partners to conduct clinical trials and seek regulatory approval for their products.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Sources:
Perspective Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Perspective Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
